Nexletol® (bempedoic acid), Nexlizet® (bempedoic acid/ezetimibe) – New/expanded indications
March 22, 2024 - Esperion announced the FDA approval of Nexletol (bempedoic acid), to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: (1) established cardiovascular disease (CVD), or (2) a high risk for a CVD event but without established CVD.
Top